Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116402 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00116402 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 15 participants.
The verdict
NCT00116402, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.
Interventions
- DRUG fluticasone and salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116402
The ClinicalTrials.gov registry entry for NCT00116402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluticasone and salmeterol is the first listed.
NCT00116402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116402 about?
NCT00116402 is a clinical study titled "A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations". The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.
What is the current status of trial NCT00116402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00116402?
The interventions under investigation include: fluticasone and salmeterol (DRUG).
Who is sponsoring clinical trial NCT00116402?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.